Latest News

Kalbe Launches Probiotic Support for the First 1000 Days of Life

Kalbe Launches Probiotic Support for the First 1000 Days of Life

Press Release No. 029/KFCP-DIR/PR/VII/20

Jakarta, 30 July 2020, PT Kalbe Farma Tbk (Kalbe) today launches a probiotic product to optimize the digestive health of Indonesian infants and toddlers' in the form of drops, called Liprolac Baby. Liprolac Baby is the pioneer of probiotic supplement to support the role of breastmilk (ASI) and the growth of children specifically in the first 1000 days of life, therefore it is appropriate to be given in the early days of a child's life. The launch of the product is marked with a health education activity through a Webinar media with the theme of 'Role of Probiotics in the First 1000 days of Life' with speakers Rayi Tanjung Sari, M.Psi. Psychologist, Pediatric Psychologist; and dr. Lupita Wijaya, Medical Executive of PT Kalbe Farma Tbk. 

"Kalbe has been consistently conducting health education for the general public, wherein in this activity the focus is the growth of children during their first 1000 days of life,” said Ridwan Ong, Pharma Marketing Director of PT Kalbe Farma Tbk. "With this activity, it is hoped that many more parents would be aware of the importance of their children's health, especially in relation with the fulfillment of nutrition both from food and supplements, children's digestive system, and the parents' participation in the golden period of growth of their child,” Ridwan continued. 

"During children's growth period, especially in the first 1000 days of life, stimulations are required where one of the methods that can be done by parents is by playing with the children in order to form positive interaction and strong emotional bonds,” said Rayi Tanjung Sari, M.Psi. Psychologist, Pediatric Psychologist. "There are 7 sensory stimulations that parents need to focus on during a child's growth: Sight (Vision), Hearing (Auditory), Smell (Olfactory), Taste (Gustatory), Touch (Tactile), Vestibular (Movement), and Proprioception (Body Position),” Rayi continued. 

"Probiotic intake in the early stages of a baby's life is acquired through breast milk as it is capable to optimize the digestive health, increase immunity, and support the child's growth and development,” said dr.Lupita Wijaya, Medical Executive of PT Kalbe Farma Tbk. "In the first 1000 days of life, the good bacteria is dominated by the Bifidobacterium sp that is present in the infant's intestines since birth, where one of the types are BB-12 probiotics that has been clinically proven to carry many benefits for babies, dr. Lupita continued. 

"Liprolac Baby contains the probiotic Bifidobacterium animalis subsp. lactis (BB-12® Suitable to be given since birth to optimize the health of the digestive system and support the child's growth,” said apt. Eric Antonius, M.M., Product Manager of PT Kalbe Farma Tbk. "Liprolac Baby is available in liquid format (oral drops), is lactose-free, gluten-free, tasteless and preservative-free, as well as practical as it does not need to be stored in the refrigerator. Liprolac Baby can be given directly onto the tongue, through a spoon; or mixed in milk or food,” apt. Eric continued. 

Kalbe at a glance
PT Kalbe Farma Tbk ("Kalbe") was established in 1966 and is one of the largest listed pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle a reliable and diverse brand portfolio; prescription drug division (Cefspan, Brainact, Broadced, etc.), Over-the-Counter drugs division (Promag, Mixagrip, Komix, Woods, Fatigon, etc.), multivitamin (Fatigon, H2, XonCe, Hevit-C, JossC1000, etc.), supplemental and instant drinks (Hydro Coco, Extra Joss), nutritional division (ChilKid, Prenagen, Diabetasol, Zee, etc.), and distribution division. Kalbe now has more than 40 subsidiaries, 14 production facilities with international standards, and employs approximately 17,000 employees, spread in more than 76 branches throughout Indonesia. Since 1991, Kalbe is listed on the Indonesia Stock Exchange (IDX: KLBF).


1086 Rate this article:

Please login or register to post comments.